课题基金 / 基金详情

Longevity assurance interventions, metabolic health and Alzheimer's Disease

Longevity assurance interventions, metabolic health and Alzheimer's Disease
长寿保证干预措施、代谢健康和阿尔茨海默病
批准号:
10200629
负责人:
Liou Sun
金额:
$49.27万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2023-05-31
关键词:
3xTg-AD mouseAPP-PS1AddressAffectAgeAgingAlzheimer like pathologyAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease riskAmericanAmyloid beta-ProteinAnimal ModelAnimalsBehavioralBiological ModelsBiology of AgingBody Weight decreasedBrainChronologyCognitive agingComb animal structureDementiaDependenceDevelopmentDietary InterventionDiseaseDisease ProgressionDisease modelEffectivenessElderlyElectrophysiology (science)ExhibitsFoundationsFutureGenerationsGeneticGerontologyGlucoseGoalsHealthHealth Care CostsHomeostasisHumanIncidenceInsulinInsulin ResistanceInterventionInvestigationLaron SyndromeLeadLearningLipidsLongevityMalignant NeoplasmsMemoryMetabolicMetabolic dysfunctionMetabolic syndromeMetabolismMethionineMitochondriaModelingMolecularMusMutant Strains MiceMutationNerve DegenerationNeurodegenerative DisordersNeurosciencesNon-Insulin-Dependent Diabetes MellitusObesityOrganismOutcomePathologicPathologyPathway interactionsPharmaceutical PreparationsPharmacologyPhenotypePhysiologicalProcessPublic HealthRattusResearchRisk FactorsRodentRodent ModelSenile PlaquesSignal PathwaySomatotropinSomatotropin-Releasing HormoneTestingWorkYeastsabeta depositionage relatedaging brainanti agingbaby boomercost effectivediabetes riskdietarydietary restrictiondisease phenotypeepidemiology studygenetic manipulationhealthspanhormonal signalsimprovedinsulin sensitivitymiddle agemodel developmentmortalitymutantnervous system disordernovelnovel strategiespathological agingpreclinical studypreventresponsesymptom treatmentsynaptic functiontau Proteinstau aggregationtherapeutically effectivetherapy development

项目摘要

项目成果

Liou Sun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The mechanisms responsible for the age dependence of the onset of neurodegeneration are unknown, which represents a fundamental problem both in neuroscience and biogerontology. Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by dementia, deposition of beta amyloid (Aβ) plaques, and neurofibrillary tau tangles. Despite progress in developing treatments for the symptomatic relief of AD, most drugs only exhibit marginal benefits and no cure currently exists. Epidemiological and preclinical studies provide strong evidence that metabolic derangements including obesity, metabolic syndrome and type 2 diabetes constitute major risk factors for age-related diseases including dementia and AD but the mechanisms involved remain to be elucidated. The GH signaling functions as a central regulator of metabolism and energy use, and it coordinates the physiological responses of the entire organism through hormonal signaling. Mutant animals with reduced GH signaling are not only long-lived, but are protected against age-associated decline in memory and learning. Methionine restriction has been shown previously to extend lifespan and delay aging in both rats and mice, dramatically decrease body weight and adiposity, and improve insulin sensitivity and ameliorate aging-associated alterations in glucose and lipid homeostasis. Thus, combing delaying aging models with AD disease models exhibiting various phenotypic effects provides a novel opportunity to develop new models that will allow studies focused on the interaction between aging, metabolism, and neurodegeneration. Our proposed study will determine if suppression of the GH signaling and methionine restriction will prevent development of behavioral, electrophysiological and histopathologic abnormalities of AD phenotype can serve as a model to study the interaction of aging with AD, providing a new level of analysis of the human brain in health and disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lifespan extension, Somatotropic signaling and Tauopathy
Longevity assurance interventions, metabolic health and Alzheimer's Disease
Longevity assurance interventions, metabolic health and Alzheimer's Disease
Longevity assurance interventions, metabolic health and Aβ toxicity
海外基金